Statistics for Phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

Total visits

views
Phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors 4

Total visits per month

views
September 2025 0
October 2025 0
November 2025 0
December 2025 0
January 2026 0
February 2026 0
March 2026 0

File Visits

views
Pcokinetics & Pcodynamics-ao-2010.pdf 5